Thromb Haemost 2017; 117(09): 1679-1687
DOI: 10.1160/TH17-03-0201
Coagulation and Fibrinolysis
Schattauer GmbH

CD32 inhibition and high dose of rhFVIII suppress murine FVIII-specific recall response by distinct mechanisms in vitro

Nadine Vollack
,
Julia Friese
,
Sabine Bergmann
,
Andreas Tiede
,
Sonja Werwitzke
Further Information

Publication History

Received: 22 March 2017

Accepted: 18 April 2017

Publication Date:
08 November 2017 (online)

Summary

Development of neutralising antibodies (inhibitors) against factor VIII (FVIII) is a frequent and severe complication of replacement therapy in haemophilia A. Previous data from haemophilia A mouse model demonstrates that both CD32 inhibition and high doses of rhFVIII prevent the differentiation of FVIII-specific memory B cells (MBCs) into antibody secreting cells (ASCs). Here, cellular targets responsible for the suppression of ASC formation by means of CD32 inhibition and high dose of rhFVIII were analysed. We investigated apoptosis on FVIII-specific MBCs using a pan caspases inhibitor, and screened for defects in rhFVIII presentation by analysing T cell release of Th1- and Th2-cytokines in vitro. Although high dose of rhFVIII suppressed ASC formation, cytokine response was not affected. Upon re-stimulation of splenocytes with high dose of rhFVIII, prevention of apoptosis fully restored the FVIII-specific recall response. In contrast, genetic deletion or inhibition of CD32 significantly altered Th1- and Th2-response. CD32 blockade and inhibition of apoptosis resulted in a partial rescue of FVIII-specific ASCs. Normal cytokine secretion could not be restored. In conclusion, suppression of FVIII-specific recall response by CD32 and high doses of rhFVIII is mediated by distinct mechanisms. High dose of rhFVIII induces apoptosis in FVIII-specific MBCs but does not influence FVIII-specific T cell response. CD32 blockade, however, may suppress the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific MBCs and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4+ T cells in vitro.

Supplementary Material to this article is available online at www.thrombosis-online.com.

 
  • References

  • 1 Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. Adv Exp Med Biol 1995; 386: 35-45.
  • 2 Ehrenforth S, Kreuz W, Scharrer I. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
  • 3 van Helden PM, van den Berg HM, Gouw SC. et al. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 644-652.
  • 4 Whelan SF, Hofbauer CJ, Horling FM. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121: 1039-1048.
  • 5 Gilles JG, Arnout J, Vermylen J. et al. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-2461.
  • 6 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
  • 7 Ettinger RA, Paz P, James EA. et al. T cells from three Hemophilia A subjects recognized the same HLA-restricted FVIII epitope with a narrow TCR repertoire. Blood. 2016 Epub ahead of print
  • 8 Reipert BM, Ahmad RU, Turecek PL. et al. Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost 2000; 84: 826-832.
  • 9 Aalberse RC, Stapel SO, Schuurman J. et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-477.
  • 10 Stevens TL, Bossie A, Sanders VM. et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255-258.
  • 11 Ettinger RA, James EA, Kwok WW. et al. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114: 1423-1428.
  • 12 Ragni MV, Bontempo FA, Lewis JH. Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC. Transfusion 1989; 29: 447-449.
  • 13 Qian J, Borovok M, Bi L. et al. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81: 240-244.
  • 14 Sasgary M, Ahmad RU, Schwarz HP. et al. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-272.
  • 15 Wu H, Reding M, Qian J. et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-133.
  • 16 Bray GL, Kroner BL, Arkin S. et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-379.
  • 17 Qian J, Collins M, Sharpe AH. et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-1329.
  • 18 Reipert BM, Sasgary M, Ahmad RU. et al. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost 2001; 86: 1345-1352.
  • 19 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97: 2750-2757.
  • 20 Hausl C, Ahmad RU, Schwarz HP. et al. Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. Blood 2004; 104: 115-122.
  • 21 Miao CH, Ye P, Thompson AR. et al. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 2006; 108: 19-27.
  • 22 Hausl C, Ahmad RU, Sasgary M. et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-3422.
  • 23 Werwitzke S, Vollack N, von Hornung M. et al. Deletion or inhibition of Fc gamma receptor 2B (CD32) prevents FVIII-specific activation of memory B cells in vitro. Thromb Haemost 2015; 114: 1127-1135.
  • 24 Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nature Rev Immunol 2008; 08: 34-47.
  • 25 Takai T, Ono M, Hikida M. et al. Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 1996; 379: 346-349.
  • 26 Zhang AH, Skupsky J, Scott DW. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice. Blood 2011; 117: 2223-2226.
  • 27 Kalippke K, Werwitzke S, von Hornung M. et al. DNA analysis from stool samples: a fast and reliable method avoiding invasive sampling methods in mouse models of bleeding disorders. Lab Anim 2009; 43: 390-393.
  • 28 Bi L, Lawler AM, Antonarakis SE. et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Gen 1995; 10: 119-121.
  • 29 Bi L, Sarkar R, Naas T. et al. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-3450.
  • 30 Liu W, Won Sohn H, Tolar P. et al. Antigen-induced oligomerization of the B cell receptor is an early target of Fc gamma RIIB inhibition. J Immunol 2010; 184: 1977-1989.
  • 31 Sohn HW, Pierce SK, Tzeng SJ. Live cell imaging reveals that the inhibitory FcgammaRIIB destabilizes B cell receptor membrane-lipid interactions and blocks immune synapse formation. J Immunol 2008; 180: 793-799.
  • 32 Chen W, Wang HG, Srinivasula SM. et al. B cell apoptosis triggered by antigen receptor ligation proceeds via a novel caspase-dependent pathway. J Immunol 1999; 163: 2483-2491.
  • 33 Williams EL, Tutt AL, French RR. et al. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcgammaRIIB (CD32B). Eur J Immunol 2012; 42: 2109-2120.
  • 34 van Haren SD, Wroblewska A, Fischer K. et al. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Rev 2012; 26: 43-49.
  • 35 Hu G, Guo D, Key NS. et al. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients. Thromb Haemost 2007; 97: 788-794.
  • 36 Silveira AC, Santana MA, Ribeiro IG. et al. The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors. BMC Hematol 2015; 15: 1
  • 37 Araujo-Jorge T, Rivera MT, el Bouhdidi A. et al. An Fc gamma RII-, Fc gamma RIII-specific monoclonal antibody (2.4G2) decreases acute Trypanosoma cruzi infection in mice. Infect Immun 1993; 61: 4925-4928.
  • 38 Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nature Rev Immunol 2010; 10: 236-247.
  • 39 Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. Nature Rev Immunol 2009; 09: 15-27.
  • 40 Stockinger B. Capacity of antigen uptake by B cells, fibroblasts or macrophages determines efficiency of presentation of a soluble self antigen (C5) to T lymphocytes. Eur J Immunol 1992; 22: 1271-1278.
  • 41 Berg M, Uellner R, Langhorne J. Fc gamma receptor II dependency of enhanced presentation of major histocompatibility complex class II peptides by a B cell lymphoma. Eur J Immunol 1997; 27: 1022-1028.
  • 42 Antoniou AN, Watts C. Antibody modulation of antigen presentation: positive and negative effects on presentation of the tetanus toxin antigen via the murine B cell isoform of FcgammaRII. Eur J Immunol 2002; 32: 530-540.
  • 43 Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.